Doudna, who spoke at The Granada Theatre in downtown Santa Barbara, invented Clustered Regularly Interspaced Short Palindromic (CRISPR)-Cas9 technology in 2012, which eventually earned her a Nobel ...
A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.
Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming revolution” in climate-adapted crops and animals. Jennifer Doudna, one of the inventors of the breakthrough gene-editing ...
CRISPR Therapeutics AG (NASDAQ:CRSP) investors still suffer from the stock's tepid momentum. It has also underperformed its healthcare sector (XLV) and biotechnology peers (XBI). As a result, the ...
Using CRISPR technology, Casgevy harvests a patient’s blood-forming stem cells, and edits them (outside the body) to spur fetal hemoglobin production. Reinserted in the patient, they work to ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA with elegant precision. But it turns out that CRISPR systems have more ...
CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...